NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.16 +0.09 (+1.48 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$6.16
Today's Range$5.97 - $6.18
52-Week Range$4.78 - $25.22
Volume142,523 shs
Average Volume101,818 shs
Market Capitalization$198.89 million
P/E Ratio-2.56
Dividend YieldN/A
Beta2.05

About Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals logoRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Debt-to-Equity RatioN/A
Current Ratio15.37
Quick Ratio15.37

Price-To-Earnings

Trailing P/E Ratio-2.56
Forward P/E Ratio-2.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.93 million
Price / Sales40.35
Cash FlowN/A
Price / CashN/A
Book Value$3.37 per share
Price / Book1.83

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-54,430,000.00
Net MarginsN/A
Return on Equity-66.83%
Return on Assets-60.01%

Miscellaneous

Employees63
Outstanding Shares32,290,000

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals (NASDAQ:RARX) issued its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.05. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

5 analysts have issued 1 year price objectives for Ra Pharmaceuticals' shares. Their forecasts range from $14.00 to $31.00. On average, they expect Ra Pharmaceuticals' share price to reach $22.00 in the next year. View Analyst Ratings for Ra Pharmaceuticals.

Are investors shorting Ra Pharmaceuticals?

Ra Pharmaceuticals saw a drop in short interest in April. As of April 13th, there was short interest totalling 1,162,371 shares, a drop of 33.3% from the March 30th total of 1,743,983 shares. Based on an average trading volume of 211,456 shares, the days-to-cover ratio is presently 5.5 days. Currently, 6.4% of the shares of the stock are sold short.

Who are some of Ra Pharmaceuticals' key competitors?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, CEO, Pres, Co-Founder & Director (Age 60)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 54)
  • Dr. Simon Read Ph.D., Chief Scientific Officer (Age 47)
  • Dr. Ramin Farzaneh-Far M.D., FACC, Chief Medical Officer (Age 41)
  • Ms. Kerry Black M.S., M.B.A., Exec. Director of Operations

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Has Ra Pharmaceuticals been receiving favorable news coverage?

Headlines about RARX stock have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news stories about the company an impact score of 43.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (17.01%), BlackRock Inc. (3.57%), Millennium Management LLC (2.08%), Foresite Capital Management IV LLC (1.39%), JPMorgan Chase & Co. (1.35%) and Eventide Asset Management LLC (1.20%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Enterprise Associates 13 L New, Harry R Weller, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Ra Pharmaceuticals.

Which major investors are buying Ra Pharmaceuticals stock?

RARX stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Foresite Capital Management IV LLC, Eventide Asset Management LLC, Acuta Capital Partners LLC, Millennium Management LLC, BlackRock Inc., JPMorgan Chase & Co. and Dimensional Fund Advisors LP. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Harry R Weller, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $6.16.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $198.89 million and generates $4.93 million in revenue each year. The company earns $-54,430,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Ra Pharmaceuticals employs 63 workers across the globe.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (RARX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ra Pharmaceuticals (NASDAQ:RARX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Ra Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.00, suggesting that the stock has a possible upside of 257.14%. The high price target for RARX is $31.00 and the low price target for RARX is $14.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.00$22.00$22.75$25.00
Price Target Upside: 257.14% upside218.38% upside255.47% upside76.93% upside

Ra Pharmaceuticals (NASDAQ:RARX) Consensus Price Target History

Price Target History for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ:RARX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018SunTrust BanksReiterated RatingBuyLowView Rating Details
3/15/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$34.00 ➝ $31.00HighView Rating Details
2/13/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00MediumView Rating Details
12/5/2017Royal Bank of CanadaReiterated RatingBuy$18.00HighView Rating Details
9/28/2017Jefferies GroupReiterated RatingBuy$25.00MediumView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Ra Pharmaceuticals (NASDAQ:RARX) Earnings History and Estimates Chart

Earnings by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ:RARX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.77)($0.57)($0.67)
Q2 20182($0.53)($0.53)($0.53)
Q3 20182($0.56)($0.54)($0.55)
Q4 20182($0.62)($0.55)($0.59)

Ra Pharmaceuticals (NASDAQ RARX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018        
5/9/2018Q1 2018($0.5570)($0.61)ViewN/AView Earnings Details
3/14/2018Q4 2017($0.6970)($0.67)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.62)($0.68)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.4950)($0.56)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.5820)($0.50)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.44)($0.73)ViewN/AView Earnings Details
11/29/2016Q3 2016($0.50)($14.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ra Pharmaceuticals (NASDAQ:RARX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ra Pharmaceuticals (NASDAQ RARX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.40%
Institutional Ownership Percentage: 75.95%
Insider Trading History for Ra Pharmaceuticals (NASDAQ:RARX)
Institutional Ownership by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ RARX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Enterprise Associates 13 L NewMajor ShareholderBuy2,000,000$6.00$12,000,000.00View SEC Filing  
2/14/2018Ra Capital Healthcare Fund LpMajor ShareholderBuy2,500,000$6.00$15,000,000.00View SEC Filing  
6/19/2017Bioventures Ltd NovartisMajor ShareholderSell56,420$21.29$1,201,181.80View SEC Filing  
6/7/2017Bioventures Ltd NovartisMajor ShareholderSell12,114$22.63$274,139.82View SEC Filing  
6/5/2017Bioventures Ltd NovartisMajor ShareholderSell19,647$23.38$459,346.86View SEC Filing  
6/1/2017Bioventures Ltd NovartisMajor ShareholderSell46,261$23.93$1,107,025.73View SEC Filing  
5/26/2017Bioventures Ltd NovartisMajor ShareholderSell5,353$25.14$134,574.42View SEC Filing  
5/24/2017Bioventures Ltd NovartisMajor ShareholderSell17,451$25.01$436,449.51View SEC Filing  
5/18/2017Bioventures Ltd NovartisMajor ShareholderSell9,019$25.50$229,984.50View SEC Filing  
5/17/2017Bioventures Ltd NovartisMajor ShareholderSell42,615$25.90$1,103,728.50View SEC Filing  
10/31/2016Harry R WellerMajor ShareholderBuy338,462$13.00$4,400,006.00View SEC Filing  
10/31/2016Rajeev M ShahDirectorBuy161,538$13.00$2,099,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ra Pharmaceuticals (NASDAQ RARX) News Headlines

Source:
DateHeadline
Ra Pharmaceuticals (RARX) Expected to Announce Earnings of -$0.53 Per ShareRa Pharmaceuticals (RARX) Expected to Announce Earnings of -$0.53 Per Share
www.americanbankingnews.com - May 17 at 1:20 AM
Q2 2018 EPS Estimates for Ra Pharmaceuticals Lowered by Analyst (RARX)Q2 2018 EPS Estimates for Ra Pharmaceuticals Lowered by Analyst (RARX)
www.americanbankingnews.com - May 14 at 1:56 AM
Equities Analysts Set Expectations for Ra Pharmaceuticals Q2 2018 Earnings (RARX)Equities Analysts Set Expectations for Ra Pharmaceuticals' Q2 2018 Earnings (RARX)
www.americanbankingnews.com - May 14 at 1:56 AM
Ra Pharmaceuticals (RARX) Receives Consensus Recommendation of "Buy" from AnalystsRa Pharmaceuticals (RARX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 13 at 1:39 AM
Ra Pharmaceuticals (RARX) Posts Quarterly  Earnings Results, Misses Expectations By $0.05 EPSRa Pharmaceuticals (RARX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 11 at 10:17 PM
Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateRa Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 9:51 AM
ChemoCentryx: Discounted, Underfollowed, And Misunderstood BiotechChemoCentryx: Discounted, Underfollowed, And Misunderstood Biotech
seekingalpha.com - May 7 at 4:28 PM
Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care ConferenceRa Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 1 at 9:38 AM
 Analysts Anticipate Ra Pharmaceuticals Inc (RARX) Will Post Earnings of -$0.57 Per Share Analysts Anticipate Ra Pharmaceuticals Inc (RARX) Will Post Earnings of -$0.57 Per Share
www.americanbankingnews.com - April 29 at 1:17 PM
Ra Pharmaceuticals Inc (RARX) Short Interest UpdateRa Pharmaceuticals Inc (RARX) Short Interest Update
www.americanbankingnews.com - April 29 at 3:12 AM
Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN MeetingRa Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting
finance.yahoo.com - April 25 at 9:47 AM
Zacks Investment Research Lowers Ra Pharmaceuticals (RARX) to SellZacks Investment Research Lowers Ra Pharmaceuticals (RARX) to Sell
www.americanbankingnews.com - April 18 at 7:30 PM
Ra Pharmaceuticals Inc (RARX) Receives Average Recommendation of "Buy" from BrokeragesRa Pharmaceuticals Inc (RARX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 1:30 AM
Ra Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.57 Per ShareRa Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - April 12 at 1:23 PM
Ra Pharmaceuticals (RARX) Upgraded to "Hold" by Zacks Investment ResearchRa Pharmaceuticals (RARX) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 9 at 1:55 PM
Ra Pharmaceuticals (RARX) Upgraded by Zacks Investment Research to "Hold"Ra Pharmaceuticals (RARX) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 8 at 5:55 PM
Short Interest in Ra Pharmaceuticals Inc (RARX) Grows By 52.2%Short Interest in Ra Pharmaceuticals Inc (RARX) Grows By 52.2%
www.americanbankingnews.com - March 30 at 4:01 AM
Ra Pharmaceuticals (RARX) Upgraded at Zacks Investment ResearchRa Pharmaceuticals (RARX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:16 PM
Zacks Investment Research Lowers Ra Pharmaceuticals (RARX) to HoldZacks Investment Research Lowers Ra Pharmaceuticals (RARX) to Hold
www.americanbankingnews.com - March 28 at 9:48 PM
Ra Pharmaceuticals Inc (RARX) Receives Average Recommendation of "Buy" from AnalystsRa Pharmaceuticals Inc (RARX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 1:30 AM
Ra Pharmaceuticals Inc (RARX) Expected to Post FY2022 Earnings of $0.23 Per ShareRa Pharmaceuticals Inc (RARX) Expected to Post FY2022 Earnings of $0.23 Per Share
www.americanbankingnews.com - March 19 at 9:48 AM
Ra Pharmaceuticals Inc Expected to Post Q1 2018 Earnings of ($0.57) Per Share (RARX)Ra Pharmaceuticals Inc Expected to Post Q1 2018 Earnings of ($0.57) Per Share (RARX)
www.americanbankingnews.com - March 19 at 1:18 AM
Ra Pharmaceuticals (RARX) Given New $31.00 Price Target at BMO Capital MarketsRa Pharmaceuticals (RARX) Given New $31.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - March 15 at 5:25 PM
Ra Pharmaceuticals (RARX) Posts Quarterly  Earnings Results, Beats Estimates By $0.03 EPSRa Pharmaceuticals (RARX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - March 15 at 1:56 PM
Ra Pharmaceuticals (RARX) Rating Reiterated by SunTrust BanksRa Pharmaceuticals (RARX) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 15 at 11:54 AM
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateRa Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 5:28 PM
Ra Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.72 Per ShareRa Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - March 9 at 5:24 PM
Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care ConferenceRa Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 9:46 AM
VHCP Management II LLC Sells 225,159 Shares of Ra Pharmaceuticals Inc (RARX)VHCP Management II LLC Sells 225,159 Shares of Ra Pharmaceuticals Inc (RARX)
www.americanbankingnews.com - March 6 at 10:50 AM
Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN MeetingRa Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN Meeting
finance.yahoo.com - March 1 at 4:40 PM
Ra Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by AnalystsRa Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 27 at 1:52 AM
Citadel Advisors LLC Has $2.55 Million Holdings in Ra Pharmaceuticals Inc (RARX)Citadel Advisors LLC Has $2.55 Million Holdings in Ra Pharmaceuticals Inc (RARX)
www.americanbankingnews.com - February 26 at 12:02 PM
Ra Pharmaceuticals Inc (RARX) Major Shareholder Purchases $12,000,000.00 in StockRa Pharmaceuticals Inc (RARX) Major Shareholder Purchases $12,000,000.00 in Stock
www.americanbankingnews.com - February 21 at 6:12 PM
-$0.72 EPS Expected for Ra Pharmaceuticals Inc (RARX) This Quarter-$0.72 EPS Expected for Ra Pharmaceuticals Inc (RARX) This Quarter
www.americanbankingnews.com - February 20 at 3:34 PM
Ra Capital Healthcare Fund Lp Buys 2,500,000 Shares of Ra Pharmaceuticals Inc (RARX) StockRa Capital Healthcare Fund Lp Buys 2,500,000 Shares of Ra Pharmaceuticals Inc (RARX) Stock
www.americanbankingnews.com - February 16 at 9:08 PM
Ra Pharmaceuticals (RARX) Prices 8.4M Common Stock Offering at $6/ShareRa Pharmaceuticals (RARX) Prices 8.4M Common Stock Offering at $6/Share
www.streetinsider.com - February 15 at 4:27 PM
Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare ConferenceRa Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 8:52 AM
Ra Pharmaceuticals Announces Pricing of Public Offering of Common StockRa Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 14 at 4:41 PM
Ra Pharmaceuticals Announces Proposed Public Offering of Common StockRa Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 14 at 9:02 AM
Ra Pharmaceuticals (RARX) Price Target Cut to $14.00Ra Pharmaceuticals (RARX) Price Target Cut to $14.00
www.americanbankingnews.com - February 13 at 11:44 AM
Ra Pharmaceuticals (RARX) & Pieris Pharmaceuticals (PIRS) Head-To-Head ReviewRa Pharmaceuticals (RARX) & Pieris Pharmaceuticals (PIRS) Head-To-Head Review
www.americanbankingnews.com - February 10 at 7:24 AM
Ra Pharmaceuticals (RARX) Downgraded to "Strong Sell" at ValuEngineRa Pharmaceuticals (RARX) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 3:56 PM
Ra Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by BrokeragesRa Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 2 at 1:36 AM
Credit Suisse Group Reiterates Outperform Rating for Ra Pharmaceuticals (RARX)Credit Suisse Group Reiterates Outperform Rating for Ra Pharmaceuticals (RARX)
www.americanbankingnews.com - January 21 at 5:34 PM
Zacks: Brokerages Expect Ra Pharmaceuticals Inc (RARX) Will Announce Earnings of -$0.72 Per ShareZacks: Brokerages Expect Ra Pharmaceuticals Inc (RARX) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - January 17 at 5:12 PM
Ra Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in DecemberRa Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in December
www.americanbankingnews.com - January 14 at 2:32 AM
Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal ImpairmentRa Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
finance.yahoo.com - January 8 at 10:56 AM
Analyzing Ra Pharmaceuticals (RARX) and Its CompetitorsAnalyzing Ra Pharmaceuticals (RARX) and Its Competitors
www.americanbankingnews.com - January 1 at 9:10 PM
Analyzing Ra Pharmaceuticals (RARX) & Its CompetitorsAnalyzing Ra Pharmaceuticals (RARX) & Its Competitors
www.americanbankingnews.com - December 30 at 5:20 AM
Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis PatientsRa Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients
finance.yahoo.com - December 21 at 4:17 PM

SEC Filings

Ra Pharmaceuticals (NASDAQ:RARX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ra Pharmaceuticals (NASDAQ:RARX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ra Pharmaceuticals (NASDAQ RARX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.